World News: 09:27 GMT Wednesday 15th May 2019. [Yahoo Business News Feed via SPi World News]
The one-time, personalized therapy, which was approved in Japan in March, will be available in the country for young people with acute lymphoblastic leukemia (ALL) and adult patients with diffuse large B-cell lymphoma (DLBCL). The so-called CAR-T therapy, which Novartis believes could treat up to 216 Japanese patients a year, potentially generating annual sales of 7.2 billion yen ($65.7 million), has been a hailed as a revolutionary, last-ditch hope for people whose cancer advanced after previous treatment. Expanding to Japan, plus ongoing efforts to resolve the U.S. problems, are part of Chief Executive Vas Narasimhan's goal of turning Kymriah into $1 billion-per-year seller.
SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.